Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04067960 · ClinicalTrials.gov registry record · Early Phase 1
Pharmacogenomics Testing in the Optimal Use of Supportive Care Medications in Stage III-IV Cancer
A Early Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 197
- Enrollment target
NCT04067960: Completed Early Phase 1 study, sponsored by Mayo Clinic.
NCT04067960 is a Early Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 197 participants, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (272% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04067960, a Early Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 197 participants
- Enrollment target
Study Summary
This early phase I trial studies how well a genetic test called pharmacogenomics works in directing the optimal use of supportive care medications in patients with stage III-IV cancer. Pharmacogenomics is the study of how genes may affect the body's response to and interaction with some prescription medications. Genes, which are inherited from parents, carry information that determines things such as eye color and blood type. Genes can also influence how patients process and respond to medications. Depending on the genetic makeup, some medications may work faster or slower or produce more or fewer side effects. Pharmacogenomics testing may help doctors learn more about how patients break down and process specific medications based on their genes and improve the quality of life of cancer patients receiving clinical care.
Primary Outcome
Patient survey responses will be compared across administration time points to look for changes in symptoms, QOL, and perceptions about PGx testing.
Interventions
- PROCEDURE Biospecimen Collection
- OTHER Quality-of-Life Assessment
- OTHER Questionnaire Administration
- OTHER Genetic Testing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 197 participants |
| Start Date | 2019-06-06 |
| Est. Completion | 2022-10-06 |
| Phase | Early Phase 1 |
What the finished NCT04067960 record still lists
NCT04067960 is an interventional study that assigns participants to a tested intervention. The registered 197 participants enrollment target is mid-sized for trials with a published cap, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (272% higher).
The record links to 0 conditions, and to 4 interventions - of which Biospecimen Collection is the first listed.
NCT04067960 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04067960 about?
NCT04067960 is a clinical study titled "Pharmacogenomics Testing in the Optimal Use of Supportive Care Medications in Stage III-IV Cancer". This early phase I trial studies how well a genetic test called pharmacogenomics works in directing the optimal use of supportive care medications in patients with stage III-IV cancer. Pharmacogenomics is the study of how genes may affect the body's response to and interaction with some prescription...
What is the current status of trial NCT04067960?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 197 participants. The study started on 2019-06-06. Estimated completion is 2022-10-06.
What interventions are being tested in trial NCT04067960?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Quality-of-Life Assessment (OTHER), Questionnaire Administration (OTHER), Genetic Testing (OTHER).
Who is sponsoring clinical trial NCT04067960?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04067960's enrollment target sits among peer trials
197 69th of 2000 higher than 1,932 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04219254 · 197 participants · Phase 1
A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
- NCT06173778 · 197 participants · Phase 2
Semaglutide for Post-Smoking Cessation Weight Management
- NCT05203328 · 198 participants · NA
Prospective Study to Evaluate High Flow Nasal Cannula With Monitored Anesthesia Care During EBUS Bronchoscopy
- NCT05426967 · 198 participants · NA
rTMS for Military TBI-related Depression
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI